Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · Real-Time Price · USD
42.98
-1.92 (-4.28%)
At close: Apr 28, 2026, 4:00 PM EDT
32.35
-10.63 (-24.73%)
After-hours: Apr 28, 2026, 5:38 PM EDT
Enliven Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Enliven Therapeutics stock have an average target of 43.4, with a low estimate of 27 and a high estimate of 56. The average target predicts an increase of 0.98% from the current stock price of 42.98.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 26, 2026.
Analyst Ratings
The average analyst rating for Enliven Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $48 → $56 | Strong Buy | Maintains | $48 → $56 | +30.29% | Mar 26, 2026 |
| Mizuho | Mizuho | Buy Maintains $41 → $45 | Buy | Maintains | $41 → $45 | +4.70% | Mar 25, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $40 → $48 | Strong Buy | Maintains | $40 → $48 | +11.68% | Jul 2, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Initiates $37 | Strong Buy | Initiates | $37 | -13.91% | Jun 16, 2025 |
| Baird | Baird | Buy Maintains $40 → $52 | Buy | Maintains | $40 → $52 | +20.99% | Jun 16, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
8.50K
EPS This Year
-2.13
from -1.83
EPS Next Year
-2.83
from -2.13
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 52,500 | ||||||
| Avg | n/a | 8,497 | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.94 | -2.37 | ||||||
| Avg | -2.13 | -2.83 | ||||||
| Low | -2.43 | -3.32 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.